Cefozopran HCl is a semisynthetic, broad-spectrum, fourth-generation cephalosporin with antibacterial activity, working by binding to and inactivates penicillin-binding proteins (PBPs).
Cefozopran (HCl) is a parenteral cephalosporin with a broad spectrum of activity against Gram-positive and Gram-negative bacteria[3]. Cefozopran hydrochloride performs a linear kinetics in healthy volunteers. The main pharmacokinetic parameters have no significant gender differences, and there is no drug accumulated with multiple doses of injection[4]. Moreover, 20- or 40-mg/kg four times a day (0.5-h infusions), provided sufficient bactericidal effects on common bacterial populations (Escherichia coli, Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa) in most typical patients[5]. Cefozopran is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies[6].
搜索
